Novelion Therapeutics Inc (NVLN) Return on Equity ROE from the first quarter 2019 to first quarter 2018 and annually, average high and low, overall ranking from Mar 31 2019 to Mar 31 2018 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Novelion Therapeutics Inc   (NVLN)

Novelion Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Novelion Therapeutics Inc in the first quarter 2019?
Due to the lack of equity, it was not possible to calculate Novelion Therapeutics Inc 's return on equity (ROE) in its first quarter 2019

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2019)
I. Quarter		 (Dec 31 2018)
IV. Quarter		 (Sep 30 2018)
III. Quarter		 (Jun 30 2018)
II. Quarter		 (Mar 31 2018)
I. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -107 -108 -113 -138 -129
Return On Equity (TTM) - - - - -404.21 %
NVLN's Total Ranking # # # # #
Equity (TTM) in Millions -119 -89 -69 -45 -13
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to NVLN Management Effectiveness >> NVLN's 5 Years Annual ROE >> Compare NVLN ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





NVLN Annual Return On Equity (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016

Total Equity in Millions -89 15 136 0 0
Y / Y Equity Change - -89 % - - -
Net Income in Millions -108 -127 -53 0 0
Y / Y Net Income Change - - - - -
Return On Equity - -848.24 % -38.94 % - -

Back to NVLN Management Effectiveness >> NVLN's 5 Years Annual ROE >> Compare NVLN ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
NVLN's' Return on Equity at Yahoo Finance
NVLN's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for NVLN's Competitors
Subscribers only: Roe for Novelion Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for NVLN's Customers




Companies with similar Return On Equity at Mar 31 2019, within Healthcare Sector ROE
Tenax Therapeutics Inc   263.35 %
Semler Scientific inc   191.29 %
Harrow Inc   168.50 %
Nrc Health  125.28 %
Zynex inc   106.15 %
Ligand Pharmaceuticals Incorporated  103.29 %
Iveric Bio Inc   97.60 %
Mettler toledo International Inc   95.87 %
Fonar Corporation  94.08 %
Cba Florida Inc   90.62 %
Oxford Immunotec Global Plc  90.11 %
Arena Pharmaceuticals Inc   84.73 %
Celgene Corp  83.92 %
Orgenesis Inc   83.46 %
Apyx Medical Corp  80.06 %
Strongbridge Biopharma plc  79.31 %
Lantheus Holdings Inc   66.48 %
Zoetis Inc   64.45 %
Eli Lilly And Company  63.77 %
Amgen Inc   61.42 %
Exelixis Inc   59.59 %
Oramed Pharmaceuticals Inc  58.65 %
Remedent Inc   58.01 %
Vertex Pharmaceuticals Inc  57.49 %
Tenet Healthcare Corp  56.06 %
3m Company  56.02 %
Viskase Holdings inc   52.99 %
Pds Biotechnology Corp  47.87 %
Lineage Cell Therapeutics Inc   42.60 %
Nektar Therapeutics  37.63 %

Date modified: 2026-09-08T15:09:34+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.